| Efficacy, safety, and biomarkers of response to azacitidine and nivolumab in relapsed/refractory acute myeloid leukemia: a nonrandomized, open-label, phase II study N Daver, G Garcia-Manero, S Basu, PC Boddu, M Alfayez, JE Cortes, ... Cancer discovery 9 (3), 370-383, 2019 | 450 | 2019 |
| Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes N Daver, P Boddu, G Garcia-Manero, SS Yadav, P Sharma, J Allison, ... Leukemia 32 (5), 1094-1105, 2018 | 180 | 2018 |
| Clinical and pathological characteristics of HIV-and HHV-8–negative Castleman disease LI Yu, M Tu, J Cortes, ZY Xu-Monette, RN Miranda, J Zhang, RZ Orlowski, ... Blood, The Journal of the American Society of Hematology 129 (12), 1658-1668, 2017 | 173 | 2017 |
| The emerging role of immune checkpoint based approaches in AML and MDS P Boddu, H Kantarjian, G Garcia-Manero, J Allison, P Sharma, N Daver Leukemia & lymphoma 59 (4), 790-802, 2018 | 122 | 2018 |
| Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs P Jain, H Kantarjian, PC Boddu, GM Nogueras-González, S Verstovsek, ... Blood advances 3 (6), 851-861, 2019 | 110 | 2019 |
| Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis P Boddu, HM Kantarjian, G Garcia-Manero, F Ravandi, S Verstovsek, ... Blood advances 1 (17), 1312-1323, 2017 | 110 | 2017 |
| PPARα-deficient ob/ob obese mice become more obese and manifest severe hepatic steatosis due to decreased fatty acid oxidation Q Gao, Y Jia, G Yang, X Zhang, PC Boddu, B Petersen, S Narsingam, ... The American journal of pathology 185 (5), 1396-1408, 2015 | 89 | 2015 |
| Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts AM Zeidan, PC Boddu, MM Patnaik, JP Bewersdorf, M Stahl, RK Rampal, ... The Lancet Haematology 7 (8), e601-e612, 2020 | 76 | 2020 |
| Gut microbiome signatures are predictive of infectious risk following induction therapy for acute myeloid leukemia JR Galloway-Peña, Y Shi, CB Peterson, P Sahasrabhojane, ... Clinical Infectious Diseases 71 (1), 63-71, 2020 | 74 | 2020 |
| Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3‐internal tandem duplication genotypes PC Boddu, TM Kadia, G Garcia‐Manero, J Cortes, M Alfayez, G Borthakur, ... Cancer 125 (7), 1091-1100, 2019 | 68 | 2019 |
| Co-occurrence of FLT3-TKD and NPM1 mutations defines a highly favorable prognostic AML group P Boddu, H Kantarjian, G Borthakur, T Kadia, N Daver, S Pierce, ... Blood advances 1 (19), 1546-1550, 2017 | 67 | 2017 |
| Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach PC Boddu, HM Kantarjian, F Ravandi, G Garcia‐Manero, S Verstovsek, ... Cancer 123 (16), 3050-3060, 2017 | 57 | 2017 |
| Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors A Alhuraiji, H Kantarjian, P Boddu, F Ravandi, G Borthakur, C DiNardo, ... American journal of hematology 93 (1), 84-90, 2018 | 53 | 2018 |
| Erythroleukemia-historical perspectives and recent advances in diagnosis and management P Boddu, CB Benton, W Wang, G Borthakur, JD Khoury, N Pemmaraju Blood reviews 32 (2), 96-105, 2018 | 47 | 2018 |
| Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces the risk of relapse P Boddu, J Jorgensen, H Kantarjian, G Borthakur, T Kadia, N Daver, ... Leukemia 32 (1), 241-244, 2018 | 44 | 2018 |
| Updates on the pathophysiology and treatment of aplastic anemia: a comprehensive review PC Boddu, TM Kadia Expert review of hematology 10 (5), 433-448, 2017 | 44 | 2017 |
| The role of thrombocytapheresis in the contemporary management of hyperthrombocytosis in myeloproliferative neoplasms: a case-based review P Boddu, L Falchi, C Hosing, K Newberry, P Bose, S Verstovsek Leukemia research 58, 14-22, 2017 | 40 | 2017 |
| Therapeutic targeting of isocitrate dehydrogenase mutant AML P Boddu, G Borthakur Expert Opinion on Investigational Drugs 26 (5), 525-530, 2017 | 38 | 2017 |
| The co-occurrence of driver mutations in chronic myeloproliferative neoplasms P Boddu, D Chihara, L Masarova, N Pemmaraju, KP Patel, S Verstovsek Annals of Hematology 97, 2071-2080, 2018 | 37 | 2018 |
| Influence of IDH on FLT3-ITD status in newly diagnosed AML P Boddu, K Takahashi, N Pemmaraju, N Daver, CB Benton, S Pierce, ... Leukemia 31 (11), 2526-2529, 2017 | 37 | 2017 |
